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T
here is a growing recognition of 
the importance of the popular 
press in the communication of 
science. The media is often the primary 
source of science information and, 
as such, can have a profound impact 
on how the public views the risks and 
beneﬁ  ts of scientiﬁ  c advances. Dorothy 
Nelkin suggests that the “media serve 
as brokers between science and the 
public, framing the social reality for 
their readers and shaping the public 
consciousness about science related 
events” [1]. 
Because of this inﬂ  uential role, many 
commentators have been highly critical 
of the quality of media reporting, 
suggesting that reporting is “hyped”, 
irresponsible, and hurtful to the 
public’s understanding of important 
scientiﬁ  c issues. In 1999, the United 
Kingdom House of Commons Science 
and Technology Committee was 
concerned enough to recommend that 
the media be governed by a Code of 
Practice that “stipulates that scientiﬁ  c 
stories should be factually accurate” [2]. 
But is it fair to point an accusing 
ﬁ  nger solely at the popular press? 
There are many examples of science 
reporting that has been less than 
perfect, such as the coverage of 
behavioural genetics and human 
cloning. And there is no doubt that 
an entertaining or controversial spin 
will win out over a muted message. But 
there is also evidence that the media 
does a surprisingly good job [3], often 
accurately conveying information 
found in peer-reviewed journals. A 
more subtle problem, and one that may 
have more long-term implications than 
simply bad reporting, is the faithful 
portrayal of commercially inﬂ  uenced 
research results.
A Marketing Message?
There is an expanding body of 
evidence that suggests that the 
increasingly commercial 
nature of biomedical 
research is having an 
impact on how science 
stories are portrayed. 
Studies have shown that 
papers in peer-reviewed 
journals are more likely to 
contain positive ﬁ  ndings if 
the research is funded by 
industry [4]. A study that 
examined pharmaceutical 
research found that 
“among the authors of 
original research papers, 
reviews and letters to 
the editor that were 
supportive of the drugs’ use, 96% 
had ﬁ  nancial relationships with the 
drugs’ manufacturers; for publications 
deemed neutral or critical the ﬁ  gure 
was only 60% and 37% respectively” 
[5,6]. To make matters worse, there is 
also evidence that negative results are 
either de-emphasised or simply not 
published [7,8]. This bias is picked up 
by the popular press and conveyed, 
largely uncritically, to the public [3].
Commercial inﬂ  uence on public 
representations of science has the 
potential to create a skewed picture of 
biomedical research—a picture that 
emphasises beneﬁ  ts over risks, and 
predictions of unrealistic breakthroughs 
over a tempered explanation of the 
incremental nature of the advancement 
of scientiﬁ  c knowledge. In the area 
of genetics, for example, there is 
concern that this commercial inﬂ  uence 
will lead to a simplistic and overly 
deterministic view of the role of genes 
in human health and may have an 
adverse impact on public dialogue [1]. 
There is also concern that it will create 
unrealistic expectations about a given 
scientiﬁ  c advance or product. In the 
context of health care, this may lead to 
inappropriate and expensive utilisation 
patterns. 
Given the increasingly close 
connection between the media’s 
portrayal of science and the broader 
agenda of commercialisation, some 
media representations can be viewed 
as a subtle form of marketing, albeit 
often inadvertent. One commentator 
has gone so far as to suggest that, to a 
large degree, “medical news is actually 
unpaid advertising” [9]. 
This is not to say that science 
reporting is part of a coordinated effort 
to promote a particular product. On 
the contrary, there is rarely a speciﬁ  c 
product to promote, and the media 
is just looking for an interesting and 
intriguing story that will help sell 
papers. However, in the long run, 
a continued, systemic trend toward 
positive, industry-inﬂ  uenced reporting 
may operate in much the same way 
as an explicit promotional campaign. 
In fact, optimistic media portrayals 
could be considered more powerful 
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than promotional campaigns. The 
message is separated from an obvious 
marketing agenda and often includes 
a trusted voice, such as a university-
based researcher. Paradoxically, this 
trust is based in part on a belief in the 
perceived independence of university 
researchers.
Balancing the Message
There is nothing inherently wrong with 
commercial involvement in biomedical 
research. After all, in most countries 
with an advanced biomedical research 
infrastructure, commercial entities, 
rightly or not, are an essential element 
of the technology-development process. 
Nevertheless, we need to be sensitive to 
the inﬂ  uence of market forces on how 
science is represented to the public. 
Eventually, the public will catch on. 
And when they do, public trust in the 
biomedical research enterprise may be 
irreparably harmed. 
In an increasingly knowledge-based 
economy, there seems to be little doubt 
that private industry will continue to 
play a signiﬁ  cant role in the funding 
of science. The research community 
must adjust to this inevitability by 
taking steps to ensure that portrayals of 
science remain as balanced as possible. 
As thoughtfully noted by Tom Wilkie: 
“If science is to manage the transition 
from its older, academic tradition to a 
new style, while keeping popular assent 
and the popular image of science as 
an impartial means of getting at the 
truth, then the scientiﬁ  c community 
itself must recognise the importance of 
maintaining impartial sources of public 
information.” [10] 
What can be done? For a start, 
reporters should always ask for and 
researchers should always offer 
information about the nature of the 
funding and the ﬁ  nancial relationship 
of the researchers to the sponsor. 
Increasingly, this information is 
disclosed in peer-reviewed journals. 
However, it may not be communicated 
in other popular representations of 
research results. As motivation, the 
research community should remember 
that the media also likes a good 
conﬂ  ict-of-interest story [11]. Complete 
transparency should be the understood 
standard practice.
The research community should 
also consider the establishment of 
various sources of independent science 
information, including a venue for the 
publishing of negative results and a 
list of respected researchers who may 
be able to provide an alternative view. 
Not only would this create an outlet 
for results that do not correspond 
with commercial interests, it would 
also serve as a resource for the media. 
Reporters are often under extremely 
tight deadlines, and it is not always 
easy to ﬁ  nd an independent second 
opinion, an indispensable component 
of balanced reporting. 
Naturally, commercial pressure isn’t 
the only source of science hype, and 
it is understandable that researchers 
may want to promote their latest 
ﬁ  ndings. But commercial inﬂ  uence 
is emerging as a known source of 
bias, and it is a phenomenon that 
could have a profound impact on 
how the public perceives the entire 
research enterprise. Developing 
strategies, starting with the modest 
ones suggested above, seems to 
be an essential element of any 
communication strategy.  
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